Brydee Cashmore, David J Tunnicliffe, Suetonia Palmer, Llyod Blythen, Jane Boag, Karam Kostner, Rathika Krishnasamy, Kelly Lambert, Andrea Miller, Judy Mullan, Maira Patu, Richard K S Phoon, Liz Rix, Natasha Trompf, David W Johnson, Robert Walker
AIM: People with chronic kidney disease experience high rates of cardiovascular disease. Cholesterol-lowering therapy is a mainstay in the management but there is uncertainty in the treatment effects on patient-important outcomes, such as fatigue and rhabdomyolysis. Here, we summarise the updated CARI Australian and New Zealand Living Guidelines on cholesterol-lowering therapy in chronic kidney disease. METHODS: We updated a Cochrane review and monitored newly published studies weekly to inform guideline development according to international standards...
April 29, 2024: Nephrology